Kosmos
EchoNous, Inc. • Radiology • 08/06/2021
Device Purpose
The Kosmos system is a portable diagnostic tool designed for healthcare professionals, integrating ultrasound imaging, electrocardiography, and digital auscultation for comprehensive patient assessment. This iteration expands its clinical utility through the incorporation of new ultrasound modes like Pulsed-Wave and Continuous-Wave Doppler, a linear array transducer for applications such as vascular and musculoskeletal imaging, and additional probe options, all facilitating synchronized data acquisition.
Summary
The Kosmos system is a diagnostic device comprised of a tablet display (either proprietary Kosmos Bridge or a user-supplied Android tablet) and a cabled probe, designed for use by healthcare professionals. Its core functionality integrates ultrasound imaging with electrocardiogram (ECG) and digital auscultation (DA) capabilities, particularly with the Kosmos Torso probe which houses both an ultrasound transducer and sealed microphones, and allows for time-synchronized acquisition of these three data types. The system can operate on battery or mains power and supports Wi-Fi for data management and software updates. The 3-lead single-channel ECG provides a timing reference for the cardiac cycle, enhancing the interpretation of concurrent ultrasound and auscultation data. This iteration of the Kosmos system significantly broadens its diagnostic ultrasound applications and operational modes. Key additions include clinical applications for Vascular/Peripheral Vascular and Musculoskeletal imaging, as well as expanded interventional guidance for procedures such as fluid drainage and nerve blocks. The system now incorporates Pulsed-Wave (PW) Doppler and Continuous-Wave (CW) Doppler modes, alongside new combined modes (B+PW, B+CW). A significant hardware update is the introduction of a linear array transducer (Kosmos Lexsa probe) and ultrasound-only probe variants (Kosmos Torso-One, Kosmos Torso-One USB), complementing the existing phased array transducer. These changes aim to improve diagnostic versatility for adult and pediatric patients in clinical care and medical education settings.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the time-synchronization of ultrasound, ECG, and digital auscultation enhance diagnostic accuracy or workflow efficiency compared to sequential or separate assessments?; What is the learning curve for healthcare professionals to effectively utilize the expanded ultrasound modes (PW/CW Doppler) and new linear array transducer applications, particularly for interventional guidance?; Are there specific patient populations or clinical scenarios where the integrated digital auscultation offers a distinct advantage over traditional stethoscopes when used alongside real-time ultrasound imaging?; What is the impact of the new probe options (Torso-One, Lexsa) on image quality and diagnostic capabilities across the expanded clinical applications (e.g., musculoskeletal, vascular) compared to the original Kosmos Torso probe?; How does the system's performance, particularly for the newly added Doppler modalities and linear array transducer, compare in terms of sensitivity and specificity to larger, cart-based ultrasound systems in their respective applications?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class C (software safety classification); Authorized before §524B enforcement
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of HBOM, OBOM detected in AI-generated device summary.
• This device was authorized before §524B took effect. Cybersecurity evidence requirements were less prescriptive at the time.
• Not detected in AI-generated device summary: SBOM, ML-BOM, SaaSBOM, CBOM, VDR/VEX. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly